Azka Ijaz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Azka Ijaz has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Areesha Wasti
Continental Medical College, Lahore, Pakistan
1 shared publication Hassan Ijaz
Department of Medicine, King Edward Medical University, Lahore, Pakistan
1 shared publication- Ibrahim Manzoor
Islamic International Medical College, Riphah International University, Rawalpindi, Pakistan
1 shared publication Mohammad Uzair Abdullah
Department of Medicine, King Edward Medical University, Lahore, Pakistan
1 shared publication- Muhammad Idrees Khan
Adam University School of Medicine, Bishkek, Chuy region, Kyrgyzstan
1 shared publication - Muhammad Shaheer Bin Faheem
Department of Medicine and Surgery, Karachi Institute of Medical Sciences, KIMS
1 shared publication
Latest Publications
- Open Access
- 3 June 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (7) , 4716-4717
Esketamine-propofol combination for colonoscopy sedation: addressing the limitations of propofol monotherapy
Was not provided for this article.
- 3 June 2026
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 88 (7) , 4716-4717
Open AccessEsketamine-propofol combination for colonoscopy sedation: addressing the limitations of propofol monotherapy
Was not provided for this article.
- Open Access
- 14 November 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (46) , e45882
Trends in adrenal cancer mortality in the US: Regional, demographic and geographic disparities from 1999 to 2020
Early-stage adrenal cancer has a 5-year survival rate of 50% to 60% which drops to 10% to 20% following metastasis. We aim to identify the adrenal cancer mortality patterns across various demographics and geographies in the U.S. from 1999 to 2020 by using a national database. Death certificate-associated datasets were retrieved from the CDC WONDER database using the ICD-10 code C74 to identify adrenal cancer patients. age-adjusted mortality rates were calculated per million population along with annual percent changes in them for all the stratifications, including sex, race, and geography. Overall, 14,622 mortalities were attributed to adrenal cancer, with AAMR decreasing from 2.429 in 1999 to 2.068 in 2020 (APC–0.7804; P <.05). Males (2.21) and non-Hispanic Whites (2.16) exhibited the highest rates. Older adults (6.09) reported the highest AAMR compared with younger populations. Further peak rates were observed among the residents of non-metropolitan areas (2.32) and the Midwest region (2.23). Overall, the mortality rates declined, but significant demographic and regional disparities exist, emphasizing the need for targeted interventions chiefly for older individuals, men, and those in non-metropolitan areas.
- 14 November 2025
- Published by Wolters Kluwer Health in Medicine
- Vol. 104 (46) , e45882
Open AccessTrends in adrenal cancer mortality in the US: Regional, demographic and geographic disparities from 1999 to 2020
Early-stage adrenal cancer has a 5-year survival rate of 50% to 60% which drops to 10% to 20% following metastasis. We aim to identify the adrenal cancer mortality patterns across various demographics and geographies in the U.S. from 1999 to 2020 by using a national database. Death certificate-associated datasets were retrieved from the CDC WONDER database using the ICD-10 code C74 to identify adrenal cancer patients. age-adjusted mortality rates were calculated per million population along with annual percent changes in them for all the stratifications, including sex, race, and geography. Overall, 14,622 mortalities were attributed to adrenal cancer, with AAMR decreasing from 2.429 in 1999 to 2.068 in 2020 (APC–0.7804; P <.05). Males (2.21) and non-Hispanic Whites (2.16) exhibited the highest rates. Older adults (6.09) reported the highest AAMR compared with younger populations. Further peak rates were observed among the residents of non-metropolitan areas (2.32) and the Midwest region (2.23). Overall, the mortality rates declined, but significant demographic and regional disparities exist, emphasizing the need for targeted interventions chiefly for older individuals, men, and those in non-metropolitan areas.